Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-10-11
DOI
10.1007/s40257-019-00475-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Multiplex quantitative analysis of tumor-infiltrating lymphocytes and immunotherapy outcome in metastatic melanoma
- (2019) Pok Fai Wong et al. CLINICAL CANCER RESEARCH
- Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma
- (2019) Robyn D. Gartrell et al. CLINICAL CANCER RESEARCH
- Prognostic and Predictive Immunohistochemistry-Based Biomarkers in Cancer and Immunotherapy
- (2019) Emanuelle M. Rizk et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.
- (2019) Eric Robinson et al. JOURNAL OF CLINICAL ONCOLOGY
- Using machine learning algorithms to predict response and toxicity to immune checkpoint inhibitors (ICIs) in melanoma patients.
- (2019) Paul Johannet et al. JOURNAL OF CLINICAL ONCOLOGY
- Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients
- (2018) Robert W. Cook et al. Diagnostic Pathology
- Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
- (2018) Michael Lattanzi et al. JNCI-Journal of the National Cancer Institute
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
- (2018) Scott J. Rodig et al. Science Translational Medicine
- Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy
- (2018) Michael Lattanzi et al. JNCI-Journal of the National Cancer Institute
- Quantitative Analysis of Immune Infiltrates in Primary Melanoma
- (2018) Robyn D. Gartrell et al. Cancer Immunology Research
- Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning
- (2018) Nicolas Coudray et al. NATURE MEDICINE
- Automated Gleason grading of prostate cancer tissue microarrays via deep learning
- (2018) Eirini Arvaniti et al. Scientific Reports
- T-Cell–Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028
- (2018) Patrick A. Ott et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Transected thin melanoma: Implications for sentinel lymph node staging
- (2017) Garth Herbert et al. JOURNAL OF SURGICAL ONCOLOGY
- NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics
- (2017) Helena Cirenajwis et al. Molecular Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
- (2017) David L. Rimm et al. JAMA Oncology
- Role of Sentinel Lymph Node Biopsy in Patients with Thin Melanoma
- (2017) Robert H. I. Andtbacka et al. Journal of the National Comprehensive Cancer Network
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas
- (2016) Heidi Wat et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Indoleamine 2,3 dioxygenase as a prognostic and follow-up marker in melanoma. A comparative study with LDH and S100B
- (2016) M.V. de Lecea et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors
- (2016) Max Schreuer et al. Journal of Translational Medicine
- Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
- (2016) Se Jin Im et al. NATURE
- Present Yourself! By MHC Class I and MHC Class II Molecules
- (2016) Kenneth L. Rock et al. TRENDS IN IMMUNOLOGY
- Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
- (2016) Douglas B. Johnson et al. Nature Communications
- The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy
- (2016) Luca Faloppi et al. Scientific Reports
- Prognostic Role of Lactate Dehydrogenase Expression in Urologic Cancers: A Systematic Review and Meta-Analysis
- (2016) Yong Zhang et al. Oncology Research and Treatment
- Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies
- (2015) Fausto Petrelli et al. ACTA ONCOLOGICA
- The multifaceted role of CD146/MCAM in the promotion of melanoma progression
- (2015) Xing Lei et al. Cancer Cell International
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- Expression of microRNA-106b and its clinical significance in cutaneous melanoma
- (2015) N. Lin et al. GENETICS AND MOLECULAR RESEARCH
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
- (2015) S. P. Patel et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Neoantigens in cancer immunotherapy
- (2015) T. N. Schumacher et al. SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- The role of osteopontin expression in melanoma progression
- (2015) Timea Kiss et al. TUMOR BIOLOGY
- Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma
- (2015) M. R. Girotti et al. Cancer Discovery
- Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
- (2015) Simon Chang-Hao Tsao et al. Scientific Reports
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
- (2015) D. B. Johnson et al. Cancer Immunology Research
- Association BetweenNRASandBRAFMutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma
- (2015) Nancy E. Thomas et al. JAMA Oncology
- Detection of Exosomal miRNAs in the Plasma of Melanoma Patients
- (2015) Susan Pfeffer et al. Journal of Clinical Medicine
- The MAPK pathway across different malignancies: A new perspective
- (2014) Mauricio Burotto et al. CANCER
- Blood mRNA Expression Profiling Predicts Survival in Patients Treated with Tremelimumab
- (2014) Y. Saenger et al. CLINICAL CANCER RESEARCH
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- Breslow Thickness, Clark Index and Ulceration Are Associated with Sentinel Lymph Node Metastasis in Melanoma Patients: A Cohort Analysis of 612 Patients
- (2014) Coline Munsch et al. DERMATOLOGY
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials
- (2014) Jason Madore et al. Pigment Cell & Melanoma Research
- Tissue prognostic biomarkers in primary cutaneous melanoma
- (2014) Mario Mandalà et al. VIRCHOWS ARCHIV
- Targeted therapy in melanoma – the role of BRAF, RAS and KIT mutations
- (2013) Simone M. Goldinger et al. EJC SUPPLEMENTS
- Phase II Trial (BREAK-2) of the BRAF Inhibitor Dabrafenib (GSK2118436) in Patients With Metastatic Melanoma
- (2013) Paolo A. Ascierto et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinicopathologic Predictors of Sentinel Lymph Node Metastasis in Thin Melanoma
- (2013) Dale Han et al. JOURNAL OF CLINICAL ONCOLOGY
- S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma
- (2013) Sail Abusaif et al. MELANOMA RESEARCH
- Mutational heterogeneity in cancer and the search for new cancer-associated genes
- (2013) Michael S. Lawrence et al. NATURE
- Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic Melanoma
- (2012) G. Erdag et al. CANCER RESEARCH
- Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma
- (2012) Farhad Azimi et al. JOURNAL OF CLINICAL ONCOLOGY
- Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
- (2012) Sandra L. Wong et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum microRNAs as biomarkers for recurrence in melanoma
- (2012) Erica B Friedman et al. Journal of Translational Medicine
- Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline
- (2012) Sandra L. Wong et al. Journal of Oncology Practice
- NRAS mutation status is an independent prognostic factor in metastatic melanoma
- (2011) John A. Jakob et al. CANCER
- Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma
- (2011) Friederike Egberts et al. EUROPEAN JOURNAL OF CANCER
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- D2-40 lymphatic marker for detecting lymphatic invasion in thin to intermediate thickness melanomas: Association with sentinel lymph node status and prognostic value—A retrospective case study
- (2011) Laurel E. Fohn et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- A High Proliferative Index of Recurrent Melanoma Is Associated with Worse Survival
- (2011) Ting J. Tu et al. ONCOLOGY
- Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma
- (2010) Rita G Ladstein et al. BMC CANCER
- Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1
- (2010) Xinyuan Zhou et al. IMMUNITY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Meta-analysis of sentinel lymph node positivity in thin melanoma (≤1 mm)
- (2009) Melanie A. Warycha et al. CANCER
- A Multimarker Prognostic Assay for Primary Cutaneous Melanoma
- (2009) M. Kashani-Sabet et al. CLINICAL CANCER RESEARCH
- Macrophage Markers in Serum and Tumor Have Prognostic Impact in American Joint Committee on Cancer Stage I/II Melanoma
- (2009) Trine O. Jensen et al. JOURNAL OF CLINICAL ONCOLOGY
- Final Version of 2009 AJCC Melanoma Staging and Classification
- (2009) Charles M. Balch et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration
- (2008) Firouzeh Niakosari et al. ARCHIVES OF DERMATOLOGY
- Prognostic versus predictive value of biomarkers in oncology
- (2008) C.N.A.M. Oldenhuis et al. EUROPEAN JOURNAL OF CANCER
- Most mammalian mRNAs are conserved targets of microRNAs
- (2008) R. C. Friedman et al. GENOME RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started